free web stats
Category

Sci-B-Vac™

VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac™

By | Press Releases, Sci-B-Vac™
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has completed a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to...
Read More

VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac™ Hepatitis B Vaccine

By | Press Releases, Sci-B-Vac™
98.8% of Patients Seroprotected at Two Months Following Second Dose of Sci-B-Vac™ VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today reported interim results from an ongoing Phase IV postmarketing study to evaluate Sci-B-Vac™, VBI’s licensed third-generation hepatitis B vaccine,...
Read More